MSL3: A Key Component of The Myeloid-Derived Suppressor System

Target Name: MSL3

NCBI ID: G10943

MSL3

MSL3: A Key Component of The Myeloid-Derived Suppressor System

MSL3, or MSL complex subunit 3, is a protein that is expressed in various tissues throughout the body. It is a key component of the myeloid-derived suppressor (MDS) system, which is a network of proteins that help to maintain the stem cell population and play a role in the development and treatment of many diseases, including leukemia.

MSL3 is a 21-kDa protein that is composed of two distinct subunits, A and B. The A subunit consists of 121 amino acids, while the B subunit consists of 119 amino acids. Both subunits contain a number of conserved domains, including a N -terminal alpha-helix, a central beta-sheet, and a C-terminal T-loop.

One of the unique features of MSL3 is its ability to form a dimeric complex with other proteins, including the myeloid-derived suppressor protein (MDS) regulatory protein PD-L1. This dimerization of MSL3 is important for its function in the MDS system, as it allows the protein to interact with multiple regulatory proteins and influence the expression of target genes.

MSL3 has also been shown to play a role in the development and progression of many diseases, including leukemia. For example, studies have shown that high levels of MSL3 are associated with the development of high-risk acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (PML-CD11). Additionally, MSL3 has been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and apoptosis.

Due to its involvement in the MDS system and its association with the development of many diseases, MSL3 has potential as a drug target or biomarker. Researchers are currently working to identify small molecules that can inhibit the activity of MSL3 and are investigating the potential clinical applications of these compounds.

In addition to its potential clinical applications, MSL3 is also of interest to researchers because of its unique structure and function. The N-terminal alpha-helical region of MSL3 contains a conserved alpha-helix that is known to be involved in protein stability and function. . This region is also known to play a role in the regulation of cellular processes, including cell adhesion and migration.

The C-terminal T-loop region of MSL3 also contains a conserved alpha-sheet that is known to be involved in the regulation of protein stability and function. This region has been shown to play a role in the regulation of cellular processes such as cell adhesion and migration.

Overall, MSL3 is a protein that has significant interest and potential as a drug target or biomarker. Its unique structure and function, as well as its involvement in the MDS system, make it an attractive target for researchers to investigate further.

Protein Name: MSL Complex Subunit 3

Functions: Has a role in chromatin remodeling and transcriptional regulation (PubMed:20018852, PubMed:20657587, PubMed:20943666, PubMed:21217699, PubMed:30224647). Has a role in X inactivation (PubMed:21217699). Component of the MSL complex which is responsible for the majority of histone H4 acetylation at 'Lys-16' which is implicated in the formation of higher-order chromatin structure (PubMed:16227571, PubMed:20657587, PubMed:16543150, PubMed:30224647). Specifically recognizes histone H4 monomethylated at 'Lys-20' (H4K20Me1) in a DNA-dependent manner and is proposed to be involved in chromosomal targeting of the MSL complex (PubMed:20657587, PubMed:20943666)

The "MSL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets